Sinovac Biotech, Ltd. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 13 of 13 Posts
Week In Review: Suzhou Innovent Files For HK IPO - $500 Million Raise Rumored
Article By: ChinaBio® Today Saturday, July 7, 2018 4:06 PM EST
Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion.
In this article: LLY, SNY, SVA, BABA, ATNX
Read
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today Saturday, September 30, 2017 5:55 PM EST
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Read
Week In Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid
Article By: ChinaBio® Today Saturday, July 1, 2017 7:14 PM EST
Shandong Sinobioway Biomedicine topped management's $402 million bid to privatize China vaccine maker Sinovac with a $459 million offer of its own. Sinovac is a Beijing vaccine company with legacy vaccines for hepatitis A and B.
In this article: AZN, GE, SVA, HCM
Read
Week In Review: Beijing's Berry Genomics Valued At $619 Million In Reverse Merger
Article By: ChinaBio® Today Saturday, December 24, 2016 4:36 PM EST
Berry Genomics, a Beijing genetic testing company, will IPO via a reverse merger with Chengdu Tianxing Instrument & Meter (SHZ: 0710) at a valuation of $619 million on China's Shenzhen market.
In this article: SVA, BGNE
Read
Week In Review: New Deals Fund China Life Science Innovation
Article By: ChinaBio® Today Saturday, September 3, 2016 1:30 PM EST
Beijing Allcure Medical Technology, a radiology oncology startup developing big data/cloud computing applications, raised $27 million in an A+ funding round.
In this article: CCM, SVA
Read
Week In Review: HighLight Capital Raising $229 Million For China Healthcare
Article By: ChinaBio® Today Saturday, May 28, 2016 12:30 PM EST
HighLight Capital of Shanghai, a healthcare early-stage private equity investor, is close to completing fundraising for its $229 million second fund, according to media reports.
In this article: SVA
Read
Week In Review: Deals Dominate China Biopharma News
Article By: ChinaBio® Today Saturday, April 2, 2016 1:53 PM EST
AliHealth, a subsidiary of China e-commerce giant Alibaba, will invest $35 million to acquire a 25% stake in China Resources Wandong Medical Equipment's medical imaging unit.
In this article: AIQ, GSK, TMO, AFFY, SVA, BABA
Read
Week In Review: BeiGene Completes $158 Million IPO In The US
Article By: ChinaBio® Today Saturday, February 6, 2016 11:43 AM EST
The company priced the offering at the top of the expected range -- $24 per share -- and increased its size from 5.5 million ADSs to 6.6 million. In its first day of trading, the company's stock rose $4.62 to $28.62, a 19% increase.
In this article: SVA, CBMG, BGNE
Read
Week In Review: BioAtla And Pfizer In $1 Billion Oncology Drug Deal
Article By: ChinaBio® Today Saturday, December 12, 2015 1:07 PM EST
BioAtla's $1 billion payout, which includes Pfizer's rights to the CTLA4 antibodies, is a combination of up-front, regulatory and sales milestone payments plus tiered royalties on potential revenues.
In this article: MRK, PFE, SVA
Read
Week In Review: Suzhou's MabSpace Raises $15 Million For Antibody Program
Article By: ChinaBio® Today Saturday, October 31, 2015 1:39 PM EST
WuXi PharmaTech has formed a partnership with Gilead Sciences under which WuXi will equip and operate a dedicated lab in Shanghai for Gilead's small-molecule new chemical entities.
In this article: LLY, WX, SVA
Read
Best Chinese Stocks For 2015
Article By: Reid Kirchenbauer Wednesday, February 11, 2015 1:29 PM EST
Chinese stocks have been among the best performing in the world in recent years. Here are some to watch in 2015.
In this article: SVA, SNP
Read
Look At This Stock – SVA
Article By: Global Economic Intersection Thursday, July 3, 2014 8:00 AM EST
SVA has been on a tear since 2012 and has recently pulled back to work off some of it's overbought condition.
In this article: SVA
Read
Look At This Stock - SVA
Article By: Jeff Pierce Tuesday, July 1, 2014 9:38 AM EST
SVA has been on a tear since 2012 and has recently pulled back to work off some of it's overbought condition. While there is a risk of this pulling back further, I think now is a good time to initiate a starter position as this could retest it's highs in the coming months.
In this article: SVA
Read
1 to 13 of 13 Posts